Tolerance of Infants With Cow's Milk Protein Allergy to Extensively Hydrolyzed Rice Protein or Casein Infant Formulas

Phase 2

Completed

• Conditions: Cow Milk Protein Sensitivity; Growth Failure; Tolerance
• Interventions: Other: Damira/Celia peptide hydrolyzed casein; Other: Picot riz/Celia rice/Sanutri arroz

• Registration Number: NCT01909661
• Lead Sponsor: Lactalis

Brief Summary

The objective of this double blinded randomized study is to assess the tolerance of two extensively protein hydrolyzed infant formulas, one based on rice protein and the other one on casein, at introduction, and after 3 months of consumption, and their efficacy on growth and on the reduction of allergy symptoms through a 3 months consumption period.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-03
• Status Verified: 2013-07
• Study First Submitted: 2013-07-18
• Study First Submitted QC: 2013-07-23
• Study First Posted: 2013-07-26
• Primary Completion: 2014-08
• Study Completion: 2014-08
• Last Update Submitted: 2015-04-16
• Last Update Posted: 2015-04-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 114

Inclusion Criteria

• Full term healthy newborns (37-42 Weeks gestation)
• Weight at birth ≥ 2500 g
• Aged between birth to 9 months
• Symptoms of allergy (Skin or digetive)
• Suspicion of cow milk protein allergy
• Infants whose parents/caregivers/legal guardians have the ability to understand and comply with the requirements of the study
• Infants whose parents/caregivers/legal guardians gave their written informed consent to the infant's participation in the study

Exclusion Criteria

• Children who have returned to breastfeeding

• Presence of any condition, that, in the opinion of the investigator is a contra-indication to the particpation of the infant in the study

• In the past 15 days, treatment or medication likely to :

  • induce confusion in the allergy tets (ex. : Skin Prick Test) and / or
  • mask the symptoms of an allergic reaction (Anti-allergy medications ; anti-histaminic, anti-leucotrienes, corticosteroids, ...)

• Newbonrs presenting a chronic or a genetic malformation, or a chromosomal or other disease, that in the opinion of the investigator could mask the study results

• Children who show signs of malnutrition, or prolonged diarrhea

• Children whose parents show no willingness to comply with study requirements

• Consumption of soya protein based, hydrolyzed protein or elemental (amino acid) formula for more than 21 days before inclusion, unless the skin prick test to cow's milk protein is positive, and the IgE level indicates the existence of IgE mediated allergy to cow's milk protein.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Damira/Celia peptide hydrolyzed casein	Damira/Celia peptide hydrolyzed casein	Extensively Hydrolyzed (EH)casein infant formula
Picot riz/Celia rice/Sanutri arroz	Picot riz/Celia rice/Sanutri arroz	Picot riz/Celia rice/Sanutri arroz Extensively Hydrolyzed (EH) rice protein infant formula

Primary Outcome Measures

Name	Time	Method
Proportion of infants who tolerate either the rice hydrolyzed protein infant formula or a hydrolyzed casein infant formula after 24h consumption.	24h	Tolerance is absence of clinical signs.

Secondary Outcome Measures

Name	Time	Method
Effectivness of the hydrolyzed protein formulas in terms of growth and allergy symptoms improvement.	3 months	Evaluate during 3 months of consumption the effectiveness of the formulas, in terms of : * infant growth, through anthropometric measures (body weight, length and head circumference); * allergy symptoms, through the improvement of the allergy symptoms.

Trial Locations

Locations (1)

Biosearch S.A.; 🇪🇸 Granada, Spain